Flagship Harbor Advisors LLC Acquires 132 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Flagship Harbor Advisors LLC boosted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 12.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,166 shares of the biotechnology company’s stock after purchasing an additional 132 shares during the quarter. Flagship Harbor Advisors LLC’s holdings in United Therapeutics were worth $411,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. USA Financial Formulas acquired a new position in shares of United Therapeutics during the third quarter worth approximately $33,000. Brooklyn Investment Group acquired a new position in United Therapeutics during the 3rd quarter valued at $33,000. Capital Performance Advisors LLP bought a new stake in United Therapeutics in the 3rd quarter valued at $82,000. MassMutual Private Wealth & Trust FSB grew its position in United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 58 shares during the last quarter. Finally, Values First Advisors Inc. bought a new position in shares of United Therapeutics during the 3rd quarter worth about $90,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analysts Set New Price Targets

UTHR has been the subject of several research reports. Oppenheimer increased their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. The Goldman Sachs Group upped their target price on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. Argus lifted their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, LADENBURG THALM/SH SH increased their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $378.36.

Insider Activity

In other news, Director Christopher Causey sold 510 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $376.63, for a total transaction of $192,081.30. Following the sale, the director now directly owns 3,675 shares of the company’s stock, valued at $1,384,115.25. This represents a 12.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Louis W. Sullivan sold 26,209 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the sale, the director now directly owns 5,051 shares of the company’s stock, valued at approximately $1,885,134.22. This represents a 83.84 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 149,048 shares of company stock worth $56,142,199. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Trading Up 0.3 %

NASDAQ UTHR opened at $370.85 on Wednesday. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $417.82. The company has a 50 day moving average of $365.60 and a 200-day moving average of $356.70. The firm has a market cap of $16.56 billion, a price-to-earnings ratio of 16.29, a PEG ratio of 0.95 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.38 EPS. On average, analysts forecast that United Therapeutics Co. will post 25.22 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.